Prasugrel

also known as Efient · Effient · EFFIENT (prasugrel) · Generic name: Prasugrel · LY-640315 · NSC-759625 · Prasu doc · Prasugrel (Effient) · +5 more

Small molecule targets P2RY12 via inhibition

Developed for: coronary artery disorder · acute coronary syndrome · myocardial infarction · ST-elevation myocardial infarction · acute myocardial infarction · intermediate coronary syndrome · sickle cell disease · atrial fibrillation
+24 more
· diabetes mellitus · brain aneurysm · thrombotic disease · aspirin-induced respiratory disease · atherosclerosis · cardiovascular disorder · chronic asthma · coronary stenosis · COVID-19 · critical illness polyneuropathy · heart disorder · hemorrhagic disease · infectious disease with sepsis · platelet aggregation, spontaneous · pneumonia · qualitative platelet defect · type 2 diabetes mellitus · arterial occlusion · coronary restenosis · ischemic stroke · migraine disorder · myocardial ischemia · platelet adenylate cyclase activity · systolic heart failure
Investigated by: Daiichi Sankyo · Eli Lilly and Company · University of Florida · University of Patras · Dong-A University · Boston Scientific Corporation
+139 more
· Ottawa Heart Institute Research Corporation · Samsung Medical Center · Seoul National University Hospital · Allies in Cardiovascular Trials Initiatives and Organized · Asan Medical Center · Assistance Publique - Hôpitaux de Paris · Italian Society of Invasive Cardiology · Medical University of Vienna · National Heart, Lung, and Blood Institute (NHLBI) · Research Maatschap Cardiologen Rotterdam Zuid · Spartan Bioscience Inc. · St. Antonius Hospital · The Medicines Company · A. Manzoni Hospital · A.R. CARD Onlus Foundation · ACE Pharmaceuticals BV · ANMCO Italian Association of Hospital Cardiologist · Abbott · Abbott Medical Devices · Academic Medical Center - University of Amsterdam · Accumetrics, Inc. · Aggredyne, Inc. · Allgen pharmaceuticals · Andalusian Public Foundation for Health Research in Seville · Andaluz Health Service · Antonio Micari · Attikon Hospital · Australian and New Zealand Intensive Care Research Centre · Azienda Ospedaliera Universitaria Policlinico "G. Martino" · Azienda USL Reggio Emilia - IRCCS · B. Braun Korea Co., Ltd. · Berry Consultants · Boston Scientific Japan K.K. · Boston Scientific Korea Co. Ltd · Brigham and Women's Hospital · Bristol-Myers Squibb · Canadian Institutes of Health Research (CIHR) · Cardialysis B.V. · CardioRISC, C-TRIC, Derry/Londonderry, Northern Ireland, UK · Cardiocentro Ticino · Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium · Centre de Recherche du Centre Hospitalier de l'Université de Montréal · Collegium Medicum w Bydgoszczy · Cordis US Corp. · Daiichi Sankyo · Dammam Central Hospital · David Antoniucci · Department of Advanced Biomedical Sciences, University of Naples Federico II, Italy · Diagnostica Stago · Dio · Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o. · Duke Clinical Research Institute · Elliot Israel, MD · Eustrategy · Faculty Hospital Kralovske Vinohrady · Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health · Ferdinando Varbella · Fondation de France · French National Institute of Health and Medical Research · Fujita Health University · Gennaro Sardella · German Heart Center Munich · Germano Di Sciascio · Giampiero Vizzari · Gianluca Di Bella · Giorgio Quadri · Global Coalition for Adaptive Research · Greca Zanda · Gyeongsang National University Hospital · HonorHealth Research Institute · Hospital Israelita Albert Einstein · IGLESIAS Juan Fernando · Imam Abdulrahman Bin Faisal University · Imperial College London · all 145 on the full record

Regulatory milestones approvals, filings & regulatory actions · 8 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Filed acute coronary syndrome 2 milestones
Filed	US (FDA)	Effient	acute coronary syndrome	2007-12-26	“Lilly, on behalf of its alliance partner, Daiichi Sankyo, submitted a new drug application to the FDA for prasugrel in December 2007.” lilly.com ↗ “new drug application that Lilly submitted for prasugrel on behalf of the alliance with Daiichi Sankyo, Limited, on December 26, 2007.” lilly.com ↗ “new drug application that Lilly submitted for prasugrel on behalf of the alliance with Daiichi Sankyo on December 26, 2007.” daiichisankyo.com ↗ “they submitted a New Drug Application (NDA) for prasugrel to the U.S. Food and Drug Administration (FDA).” lilly.com ↗ “submitted a New Drug Application to the U.S. Food and Drug Administration for prasugrel in December 2007” lilly.com ↗ “submitted a New Drug Application (NDA) for prasugrel to the U.S. Food and Drug Administration (FDA).” lilly.com ↗
Filed	EU (EMA)	—	acute coronary syndrome	—	“Lilly, on behalf of the alliance, also submitted a Marketing Authorization Application for prasugrel to the European Medicines Agency in February 2008.” lilly.com ↗
Filed ischemic stroke 1 milestone
Filed	Japan (PMDA)	—	ischemic stroke	2020-12-15	“prasugrel), was filed in Japan to expand the indication for prevention of recurrence of ischemic stroke as a partial change” daiichisankyo.com ↗
Filed myocardial ischemia 1 milestone
Filed	Japan (PMDA)	—	myocardial ischemia	2013-06-18	“has submitted a New Drug Application to the Ministry of Health, Labour and Welfare in Japan” daiichisankyo.com ↗
Approved Indication not stated 3 milestones
Label expansions (2)	US (FDA)	EFFIENT	—	2013-10-16 – 2016-07-12	fda.gov ↗
Approved	US (FDA)	EFFIENT	—	2009-07-10	fda.gov ↗
Approved	EU (EMA)	Efient	—	2009-02-24	europa.eu ↗

Trials 119 · started per year

today

EU approved 2009

US approved 2009

20032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 111 trials · 2 met primary
Phase 1	NCT03430661	Jan 2018 → May 2019	—	Viatris Innovation GmbH	Completed	No outcome recorded
Phase 1	NCT03054207	Jun 2015 → Apr 2017	HIV infectious disease	Jules Desmeules	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT02075268	Jan → Feb 2014	—	Asan Medical Center	Unknown	No outcome recorded
Phase 1	NCT01876797	Jul → Aug 2013	—	Asan Medical Center	Completed	No outcome recorded
Phase 1	NCT01648790	Jul → Aug 2012	—	Eli Lilly and Company	Completed	No outcome recorded
Phase 1	NCT01346800	Feb → Jun 2011	—	University Hospital, Geneva	Completed	No outcome recorded
Phase 1	NCT01178099	Jul 2010 → Jan 2011	sickle cell disease	Eli Lilly and Company	Completed	No outcome recorded
Phase 1	NCT01107912	Mar 2010 → Oct 2011	coronary artery disorder	Eli Lilly and Company	Completed	Met primary
Phase 1	NCT01107925	Mar 2010 → Aug 2011	coronary artery disorder	Eli Lilly and Company	Completed	Met primary
Phase 1	NCT01107899	Oct 2009 → Dec 2010	acute coronary syndrome	Eli Lilly and Company	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT01591317	Mar → May 2009	—	Eli Lilly and Company	Completed	No outcome recorded

Phase 215 trials · 3 met primary · 2 missed
Phase 2	NCT04766437	Feb 2021 → Sep 2022	acute coronary syndrome	Academic Medical Center - University of Amsterdam	Completed	No outcome recorded
Phase 2	NCT03606642	Nov 2018 → Dec 2021	atherosclerosis, coronary artery disorder	HonorHealth Research Institute	Terminated	No outcome recorded
Phase 2	NCT01979445	Dec 2013 → Jan 2014	coronary artery disorder	The Medicines Company	Completed	No outcome recorded
Phase 2	NCT01852019	Jun → Jul 2013	coronary artery disorder	The Medicines Company	Completed	No outcome recorded
Phase 2	NCT02285751	Nov 2012 → Jul 2020	critical illness polyneuropathy	Medical University of Vienna	Unknown	No outcome recorded
Phase 2	NCT01597375	Aug 2012 → Dec 2016	aspirin-induced respiratory disease	Elliot Israel, MD	Completed	No outcome recorded
Phase 2	NCT01476696	Nov 2011 → Nov 2012	sickle cell disease	Eli Lilly and Company	Completed	No outcome recorded
Phase 2	NCT01167023	Jul 2010 → Jun 2011	sickle cell disease	Eli Lilly and Company	Completed	No outcome recorded
Phase 2	NCT01115738	May 2010 → Nov 2011	acute coronary syndrome	Eli Lilly and Company	Completed	Missed primary
Phase 2	NCT00910299	Jul 2009 → Apr 2011	coronary artery disorder	Eli Lilly and Company	Terminated	No outcome recorded
Phase 2	NCT00642174	Apr 2008 → Jan 2009	coronary artery disorder, diabetes mellitus	Eli Lilly and Company	Completed	Met primary
Phase 2	NCT00385944	Mar → Oct 2007	acute coronary syndrome	Eli Lilly and Company	Completed	Met primary
Phase 2	NCT00357968	Aug 2006 → Jun 2007	coronary artery disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 2	NCT00356135	Jul 2006 → Dec 2008	acute coronary syndrome, arteriosclerosis disorder	Eli Lilly and Company	Completed	Met primary
Phase 2	NCT00059215	Apr 2003 → Jan 2004	heart disorder	Eli Lilly and Company	Completed	Missed primary

Phase 2/34 trials
Phase 2/3	NCT05657041	Apr 2023 → Aug 2024	coronary artery disorder	St. Antonius Hospital	Unknown	No outcome recorded
Phase 2/3	NCT02044146	Sep 2014 → Oct 2016	acute coronary syndrome	Ottawa Heart Institute Research Corporation	Completed	No outcome recorded
Phase 2/3	NCT01452139	Sep 2011 → Sep 2012	ST-elevation myocardial infarction	Ottawa Heart Institute Research Corporation	Completed	No outcome recorded
Phase 2/3	NCT01184300	Aug 2010 → Jul 2011	acute coronary syndrome, coronary artery disorder	Ottawa Heart Institute Research Corporation	Completed	No outcome recorded
Phase 328 trials · 4 met primary · 3 missed
Phase 3	NCT07582835	Apr 2026 → Apr 2028 expected	acute coronary syndrome, coronary artery disorder	Cardiocentro Ticino	Recruiting	No outcome recorded
Phase 3	NCT07195149	Nov 2025 → Apr 2030 expected	coronary artery disorder	Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.	Recruiting	No outcome recorded
Phase 3	NCT05952206	Oct 2023 → Jan 2027 expected	coronary artery disorder	iVascular S.L.U.	Active not recruiting	No outcome recorded
Phase 3	NCT05903976	Jun 2023 → Jun 2025	acute coronary syndrome, coronary artery disorder	Azienda Ospedaliera Universitaria Policlinico "G. Martino"	Unknown	No outcome recorded
Phase 3	NCT05779059	Apr 2023 → Dec 2024	acute coronary syndrome, intermediate coronary syndrome, myocardial infarction	Collegium Medicum w Bydgoszczy	Unknown	No outcome recorded
Phase 3	NCT04360720	Oct 2020 → Nov 2024	acute coronary syndrome	Hospital Israelita Albert Einstein	Completed	No outcome recorded
Phase 3	NCT02944123	Sep 2016 → Feb 2020	acute coronary syndrome	Dong-A University	Completed	No outcome recorded
Phase 3	NCT02735707	Apr 2016 → Feb 2026 overdue	pneumonia	UMC Utrecht	Recruiting	Mixed
Phase 3	NCT01774838	Oct 2014 → Jun 2015	acute coronary syndrome, intermediate coronary syndrome	University of Cologne	Completed	No outcome recorded
Phase 3	NCT02075125	Jan 2014 → Apr 2015	ST-elevation myocardial infarction	Dong-A University	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT01641510	Oct 2013 → Oct 2018	acute coronary syndrome	Dong-A University	Completed	No outcome recorded
Phase 3	NCT01794000	Apr 2013 → Jul 2015	sickle cell disease	Eli Lilly and Company	Terminated	Missed primary
Phase 3	NCT01778842	Mar → Jun 2013	coronary artery disorder	Gennaro Sardella	Unknown	No outcome recorded
Phase 3	NCT01560780	Feb 2013 → Apr 2018	—	VA Office of Research and Development	Completed	No outcome recorded
Phase 3	NCT01609647	Sep 2012 → Dec 2014	acute coronary syndrome	Dong-A University	Completed	Met primary
Phase 3	NCT01543932	Jul 2012 → Dec 2013	coronary artery disorder	University of Roma La Sapienza	Completed	No outcome recorded
Phase 3	NCT01515345	Jul 2011 → Jan 2013	coronary artery disorder, platelet aggregation, spontaneous	Kaiser Franz Josef Hospital	Completed	No outcome recorded
Phase 3	NCT01327534	May 2011 → Mar 2013	ST-elevation myocardial infarction	Stiftung Institut fuer Herzinfarktforschung	Completed	No outcome recorded
Phase 3	NCT01338909	Apr → Sep 2011	myocardial infarction	University of Patras	Completed	No outcome recorded
Phase 3	NCT01598337	Apr 2011 → Dec 2013	coronary artery disorder	Prince Sultan Cardiac Center, Adult Cardiology Department.	Unknown	No outcome recorded
Phase 3	NCT01304472	Feb → Apr 2011	coronary artery disorder	University of Patras	Completed	No outcome recorded
Phase 3	NCT01155765	May → Jul 2010	chronic renal failure syndrome	University of Patras	Completed	No outcome recorded
Phase 3	NCT01336348	Apr 2010 → Jun 2011	ST-elevation myocardial infarction	Università degli Studi di Ferrara	Completed	No outcome recorded
Phase 3	NCT01109784	Apr → Jul 2010	acute coronary syndrome, coronary artery disorder	University of Patras	Completed	Met primary
Phase 3	NCT01015287	Dec 2009 → Jan 2013	acute coronary syndrome	Eli Lilly and Company	Completed	Missed primary
Phase 3	NCT00830960	Feb 2009 → Jun 2010	acute coronary syndrome	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00699998	Jun 2008 → Apr 2012	acute coronary syndrome	Eli Lilly and Company	Completed	Missed primary
Phase 3	NCT00097591	Nov 2004 → Jul 2007	acute coronary syndrome, coronary atherosclerosis	Eli Lilly and Company	Completed	Met primary

Phase 453 trials · 7 met primary · 9 missed
Phase 4	NCT07507500	Sep 2026 → Jul 2029 expected	acute myocardial infarction	Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz	Recruiting	No outcome recorded
Phase 4	NCT06916520	Nov 2025 → Apr 2026 overdue	coronary artery disorder	J.P.S Henriques	Recruiting	No outcome recorded
Phase 4	NCT07025148	Oct 2025 → Aug 2027 expected	coronary artery disorder	University of Florida	Recruiting	No outcome recorded
Phase 4	NCT06821191	Mar 2025 → Nov 2026 expected	coronary artery disorder	University of Florida	Recruiting	No outcome recorded
Phase 4	NCT06691191	Jan 2025 → Aug 2026 overdue	coronary artery disorder	University of Florida	Recruiting	No outcome recorded
Phase 4	NCT06588595	Nov 2024 → Aug 2027 expected	coronary artery disorder	University of Florida	Recruiting	No outcome recorded
Phase 4	NCT06613191	Oct 2024 → Dec 2025 overdue	coronary artery disorder, peripheral vascular disease	Ochsner Health System	Not yet recruiting	No outcome recorded
Phase 4	NCT05773989	Jan → Dec 2024	coronary artery disorder	St. Antonius Hospital	Unknown	No outcome recorded
Phase 4	NCT05955365	Dec 2023 → Dec 2027 expected	atrial fibrillation	Insel Gruppe AG, University Hospital Bern	Recruiting	No outcome recorded
Phase 4	NCT06400940	Aug 2023 → Aug 2026 overdue	brain aneurysm	Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health	Recruiting	No outcome recorded
Phase 4	NCT05681702	Feb 2023 → Dec 2026 expected	coronary artery disorder	University of Florida	Recruiting	No outcome recorded
Phase 4	NCT05491200	Jul 2022 → Aug 2027 expected	ST-elevation myocardial infarction	Research Maatschap Cardiologen Rotterdam Zuid	Recruiting	No outcome recorded
Phase 4	NCT05262803	Jun 2022 → Dec 2028 expected	myocardial infarction	Rikke Sorensen	Recruiting	No outcome recorded
Phase 4	NCT05223335	Mar 2022 → Mar 2023	hemorrhagic disease	Mayo Clinic	Completed	No outcome recorded
Phase 4	NCT05183178	Feb 2022 → Aug 2025	acute coronary syndrome	Vastra Gotaland Region	Completed	No outcome recorded
Phase 4	NCT05066789	Jan 2022 → Mar 2024	coronary artery disorder	Samsung Medical Center	Terminated	No outcome recorded
Phase 4	NCT04981041	Dec 2021 → May 2026	acute coronary syndrome, atrial fibrillation	Ludwig-Maximilians - University of Munich	Completed	No outcome recorded
Phase 4	NCT04668144	Feb 2021 → Feb 2023	acute coronary syndrome, coronary artery disorder	University of Florida	Completed	Missed primary
Phase 4	NCT04505774	Sep 2020 → Aug 2023	COVID-19	Matthew Neal MD	Completed	Missed primary
Phase 4	NCT04734353	Jan 2020 → Jun 2021	coronary artery disorder	Gyeongsang National University Hospital	Unknown	No outcome recorded
Phase 4	NCT02302508	Sep 2019 → Dec 2020	diabetes mellitus	University of Montreal Hospital Centre (CHUM)	Withdrawn	No outcome recorded Stop: Business
Phase 4	NCT03581409	Oct 2018 → Jan 2021	brain aneurysm	Seoul National University Hospital	Completed	Met primary
Phase 4	NCT03672097	Oct 2018 → Aug 2020	acute coronary syndrome	Daiichi Sankyo	Completed	No outcome recorded
Phase 4	NCT03387826	Jan 2018 → Jan 2019	coronary artery disorder, diabetes mellitus, kidney disorder, myocardial infarction	Attikon Hospital	Completed	No outcome recorded
Phase 4	NCT05643586	Dec 2017 → Apr 2019	coronary artery disorder	Germano Di Sciascio	Completed	No outcome recorded
Phase 4	NCT03296540	Nov 2017 → May 2021	cardiovascular disorder	Maasstad Hospital	Completed	Missed primary
Phase 4	NCT02605447	Feb 2016 → Jul 2019	coronary artery disorder	Boston Scientific Corporation	Completed	No outcome recorded
Phase 4	NCT02601157	Jan 2016 → Aug 2021	intermediate coronary syndrome, myocardial infarction	Seoul National University Hospital	Completed	Mixed
Phase 4	NCT02548611	Sep 2015 → Aug 2018	intermediate coronary syndrome	LMU Klinikum	Terminated	Missed primary Stop: Enrollment
Phase 4	NCT02376283	Mar 2015 → Nov 2016	acute myocardial infarction	The Royal Wolverhampton Hospitals NHS Trust	Completed	No outcome recorded
Phase 4	NCT02642419	Jan 2015 → Dec 2017	atrial fibrillation	Japan Cardiovascular Research Foundation	Unknown	Met primary
Phase 4	NCT02251249	Dec 2014 → Sep 2016	acute myocardial infarction, gastroparesis	University Hospital, Bordeaux	Completed	No outcome recorded
Phase 4	NCT02212028	Oct 2014 → Aug 2015	coronary artery disorder	University of Florida	Completed	Met primary
Phase 4	NCT02193971	Jul 2014 → Oct 2020	acute coronary syndrome	Seoul National University Hospital	Completed	Met primary
Phase 4	NCT01957540	Jun 2014 → Dec 2015	coronary artery disorder	University of Patras	Completed	Missed primary
Phase 4	NCT01823185	Mar 2013 → Jan 2016	coronary artery disorder, ischemic disease, myocardial infarction, thrombotic disease	Imam Abdulrahman Bin Faisal University	Unknown	No outcome recorded
Phase 4	NCT02808767	Jan 2013 → May 2016	acute myocardial infarction	Faculty Hospital Kralovske Vinohrady	Completed	No outcome recorded
Phase 4	NCT01790854	Nov 2012 → Oct 2014	acute coronary syndrome	David Antoniucci	Terminated	No outcome recorded
Phase 4	NCT01777503	Nov 2012 → Jan 2017	acute coronary syndrome, coronary atherosclerosis	Azienda USL Reggio Emilia - IRCCS	Completed	Missed primary
Phase 4	NCT01684813	Oct 2012 → Oct 2013	acute coronary syndrome, type 2 diabetes mellitus	Andalusian Public Foundation for Health Research in Seville	Completed	Met primary
Phase 4	NCT01587651	Mar 2012 → Feb 2013	coronary artery disorder	Daiichi Sankyo	Completed	No outcome recorded
Phase 4	NCT01538446	Mar 2012 → May 2016	acute coronary syndrome	Assistance Publique - Hôpitaux de Paris	Completed	Missed primary
Phase 4	NCT01452152	Feb 2012 → Jul 2013	acute coronary syndrome	University of Maryland, Baltimore	Terminated	No outcome recorded
Phase 4	NCT01477775	Jan 2012 → Dec 2014	acute coronary syndrome, coronary artery disorder	Italian Society of Invasive Cardiology	Unknown	No outcome recorded
Phase 4	NCT01463150	Oct 2011 → Jul 2012	qualitative platelet defect	University of Patras	Completed	Met primary
Phase 4	NCT01612884	Aug 2011 → Mar 2017	coronary artery disorder, thrombotic disease	Indiana University	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT01305369	Mar → Dec 2011	chronic asthma	University of Milan	Completed	No outcome recorded
Phase 4	NCT01260584	Nov 2010 → Sep 2011	coronary artery disorder	Daiichi Sankyo	Completed	Met primary
Phase 4	NCT01069003	Apr 2010 → Apr 2014	coronary artery disorder	Medtronic Vascular	Completed	No outcome recorded
Phase 4	NCT01014624	Feb → May 2010	coronary artery disorder	Daiichi Sankyo	Completed	No outcome recorded
Phase 4	NCT01099566	Nov 2009 → Oct 2010	infectious disease with sepsis	Medical University of Vienna	Completed	No outcome recorded
Phase 4	NCT00976092	Sep 2009 → Feb 2014	myocardial infarction	German Heart Center Munich	Unknown	Missed primary
Phase 4	NCT00827411	Jan 2009 → Mar 2012	acute coronary syndrome, coronary artery disorder	Assistance Publique - Hôpitaux de Paris	Completed	Missed primary

Phase not applicable8 trials · 2 met primary
—	NCT05650411	Apr 2026 → May 2028 expected	coronary stenosis	IGLESIAS Juan Fernando	Recruiting	No outcome recorded
—	NCT05117866	Sep 2020 → Jul 2024 overdue	acute coronary syndrome, coronary artery disorder	Meditrix Corp	Active not recruiting	No outcome recorded
—	NCT03469856	Feb 2018 → Jul 2019	—	Pedro A. Lemos	Unknown	No outcome recorded
—	NCT03111420	Jan 2017 → Jun 2018	platelet disorder, undefined	Aggredyne, Inc.	Completed	No outcome recorded
—	NCT02865824	Jan 2016 → Dec 2018	polyp of colon	Incheon St.Mary's Hospital	Unknown	No outcome recorded
—	NCT02079194	Mar 2014 → Jul 2018	coronary artery disorder	Samsung Medical Center	Unknown	Met primary
—	NCT01701453	Aug 2012 → Nov 2017	acute coronary syndrome	Samsung Medical Center	Unknown	Met primary
—	NCT01212302	Oct 2008 → Mar 2010	coronary artery disorder	Ruhr University of Bochum	Completed	No outcome recorded
Comparator or background therapy79 trials
Phase 1	NCT02243137 Background	May 2013 → Jun 2014	—	David Vivas	Completed	Met primary
Phase 1	NCT01430091 Comparator	Sep → Oct 2011	sickle cell disease	Eli Lilly and Company	Completed	No outcome recorded
Phase 2	NCT07032389 Background	Dec 2025 → Jun 2030 expected	acute coronary syndrome	University of Texas Southwestern Medical Center	Recruiting	No outcome recorded
Phase 2	NCT05514938 Comparator	Nov 2022 → May 2025	acute coronary syndrome, coronary artery disorder, lip disorder	University of Texas Southwestern Medical Center	Completed	Missed primary
Phase 2	NCT02507323 Comparator	Feb 2016 → Aug 2017	cardiovascular disorder	Yochai Birnbaum	Withdrawn	No outcome recorded
Phase 2	NCT01103440 Background	Apr 2007 → Jun 2009	—	Icahn School of Medicine at Mount Sinai	Completed	No outcome recorded
Phase 3	NCT07629635 Comparator	Oct 2026 → Dec 2027 expected	migraine disorder, patent foramen ovale	Columbia University	Recruiting	No outcome recorded
Phase 3	NCT04445623 Comparator	Jul → Oct 2020	COVID-19, thrombotic disease	Azienda Ospedaliera Universitaria Integrata Verona	Unknown	No outcome recorded
Phase 3	NCT02866175 Background	Feb 2017 → Jun 2019	atrial fibrillation	Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company	Completed	Met primary
Phase 3	NCT01830543 Background	May 2013 → Jul 2016	atrial fibrillation	Janssen Scientific Affairs, LLC	Completed	Met primary
Phase 3	NCT01531114 Comparator	May 2013 → Jul 2015	ST-elevation myocardial infarction	Gennaro Sardella	Completed	No outcome recorded
Phase 3	NCT01835353 Comparator	Jun 2012 → Jul 2013	qualitative platelet defect	University of Patras	Completed	No outcome recorded
Phase 3	NCT02070159 Comparator	Dec 2011 → Dec 2012	coronary artery disorder	Dong-A University	Completed	No outcome recorded
Phase 3	NCT01465828 Comparator	Oct 2011 → Jan 2012	acute coronary syndrome	Gennaro Sardella	Completed	No outcome recorded
Phase 3	NCT01505790 Comparator	Jul 2011 → May 2012	acute coronary syndrome	Assistance Publique Hopitaux De Marseille	Completed	No outcome recorded
Phase 3	NCT01360437 Comparator	May → Dec 2011	acute coronary syndrome, coronary artery disorder	University of Patras	Completed	Met primary
Phase 3	NCT01510327 Background	Oct 2009 → Feb 2010	coronary artery disorder	Boston Scientific Corporation	Completed	No outcome recorded
Phase 3	NCT01500434 Background	Feb 2009 → Mar 2011	coronary artery disorder	Boston Scientific Corporation	Completed	No outcome recorded
Phase 3	NCT00823212 Background	Jan 2009 → Sep 2010	coronary atherosclerosis	Boston Scientific Corporation	Completed	No outcome recorded
Phase 4	NCT07684742 Comparator	Jul 2026 → Jul 2031 expected	ST-elevation myocardial infarction, acute coronary syndrome, intermediate coronary syndrome	Gyeongsang National University Hospital	Not yet recruiting	No outcome recorded
Phase 4	NCT06763744 Comparator	Jun 2025 → Jul 2029 expected	acute coronary syndrome, bleeding disorder, vascular-type	Samsung Medical Center	Not yet recruiting	No outcome recorded
Phase 4	NCT06718179 Background	Nov 2024 → Nov 2029 expected	acute coronary syndrome	Odense University Hospital	Recruiting	No outcome recorded
Phase 4	NCT05709626 Comparator	Feb 2023 → Jan 2025 overdue	ST-elevation myocardial infarction	Kindai University	Recruiting	No outcome recorded
Phase 4	NCT05767723 Comparator	Feb 2023 → May 2025 overdue	acute coronary syndrome	Hospital Israelita Albert Einstein	Active not recruiting	No outcome recorded
Phase 4	NCT05359224 Comparator	Jun 2022 → Jul 2025	brain aneurysm	Yonsei University	Unknown	No outcome recorded
Phase 4	NCT04609111 Comparator	Jan 2021 → Dec 2023	acute coronary syndrome	Kyoto University, Graduate School of Medicine	Unknown	No outcome recorded
Phase 4	NCT04014803 Comparator	Jan 2020 → Jun 2027 expected	coronary artery disorder	Samsung Medical Center	Recruiting	No outcome recorded
Phase 4	NCT04006288 Comparator	Sep 2019 → Jan 2022	coronary artery disorder	University of Florida	Completed	No outcome recorded
Phase 4	NCT03489863 Comparator	May 2018 → Mar 2019	coronary artery disorder	University of Florida	Completed	No outcome recorded
Phase 4	NCT03273075 Comparator	Sep 2017 → May 2021	acute coronary syndrome, cardiac arrest	Medical University of Vienna	Unknown	No outcome recorded
Phase 4	NCT03027934 Comparator	Aug → Oct 2017	diabetes mellitus	CirQuest Labs, LLC	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT02978040 Comparator	Jul 2017 → Aug 2019	ST-elevation myocardial infarction, coronary artery disorder	Insel Gruppe AG, University Hospital Bern	Completed	Mixed
Phase 4	NCT03062319 Comparator	Apr 2017 → Jul 2023	atherosclerosis, atrial fibrillation, ischemic stroke	National Hospital Organization Osaka National Hospital	Terminated	No outcome recorded
Phase 4	NCT05247385 Comparator	Mar 2017 → Feb 2021	coronary artery disorder	University of Sao Paulo	Completed	No outcome recorded
Phase 4	NCT03016611 Comparator	Feb → Dec 2017	ST-elevation myocardial infarction, acute coronary syndrome	Sheba Medical Center	Unknown	No outcome recorded
Phase 4	NCT02545933 Background	Feb 2016 → May 2019	myocardial infarction	University of Florida	Completed	Met primary
Phase 4	NCT02587260 Comparator	Dec 2015 → Feb 2017	cardiovascular disorder	Erasmus Medical Center	Completed	No outcome recorded
Phase 4	NCT02487732 Comparator	Jul 2015 → Aug 2016	acute coronary syndrome	Korea University Anam Hospital	Completed	No outcome recorded
Phase 4	NCT02422888 Comparator	May 2015 → Oct 2017	myocardial infarction	Amsterdam UMC, location VUmc	Unknown	Missed primary
Phase 4	NCT02261922 Comparator	Oct 2014 → Oct 2015	platelet adenylate cyclase activity	Hotel Dieu de France Hospital	Unknown	No outcome recorded
Phase 4	NCT02118870 Comparator	Jun 2014 → Sep 2017	acute coronary syndrome	Diagram B.V.	Completed	No outcome recorded
Phase 4	NCT02108808 Comparator	Apr → Oct 2014	—	University of Patras	Completed	No outcome recorded
Phase 4	NCT02065479 Comparator	Mar 2014 → Apr 2019	coronary artery disorder	University of Florida	Completed	No outcome recorded
Phase 4	NCT02032303 Comparator	Feb → Dec 2014	ST-elevation myocardial infarction, acute coronary syndrome, intermediate coronary syndrome	Azienda Policlinico Umberto I	Unknown	No outcome recorded
Phase 4	NCT01869309 Comparator	Jan 2014 → Dec 2015	coronary artery disorder	LifeBridge Health	Unknown	No outcome recorded
Phase 4	NCT01944800 Comparator	Sep 2013 → Jul 2019	acute coronary syndrome	German Heart Center Munich	Completed	No outcome recorded
Phase 4	NCT01959451 Comparator	Sep 2013 → May 2016	acute coronary syndrome	LMU Klinikum	Completed	Met primary
Phase 4	NCT01951001 Comparator	Jul 2013 → Jun 2015	acute coronary syndrome, hemorrhagic disease, thrombotic disease	Gyeongsang National University Hospital	Completed	No outcome recorded
Phase 4	NCT02215993 Comparator	Jul 2013 → Sep 2014	acute coronary syndrome, blood platelet disease	Federal University of São Paulo	Completed	No outcome recorded
Phase 4	NCT01789814 Comparator	Jul 2013 → Jul 2014	coronary artery disorder	Tufts Medical Center	Completed	No outcome recorded
Phase 4	NCT02317198 Comparator	Jun 2013 → Nov 2018	acute coronary syndrome, intermediate coronary syndrome, myocardial infarction	St. Antonius Hospital	Completed	Met primary
Phase 4	NCT01765400 Comparator	May 2013 → Dec 2015	systolic heart failure	University of Nebraska	Completed	No outcome recorded
Phase 4	NCT02402491 Comparator	Jan 2013 → Jun 2015	—	Beijing Anzhen Hospital	Unknown	No outcome recorded
Phase 4	NCT01805570 Comparator	Nov 2012 → Mar 2013	myocardial infarction	David Antoniucci	Completed	No outcome recorded
Phase 4	NCT01642966 Comparator	Sep 2012	acute coronary syndrome	University of Patras	Completed	No outcome recorded
Phase 4	NCT01700322 Comparator	Aug 2012 → Jul 2016	coronary artery disorder	Johannes Gutenberg University Mainz	Completed	No outcome recorded
Phase 4	NCT01642940 Comparator	Jun → Sep 2012	acute coronary syndrome, coronary artery disorder	University of Patras	Completed	No outcome recorded
Phase 4	NCT01589978 Background	May 2012 → Aug 2014	coronary artery disorder	Boston Scientific Corporation	Completed	No outcome recorded
Phase 4	NCT01339026 Comparator	Feb 2012 → Sep 2013	acute coronary syndrome	Royal Brompton & Harefield NHS Foundation Trust	Terminated	No outcome recorded
Phase 4	NCT01510171 Comparator	Jan → Jun 2012	ST-elevation myocardial infarction	Careggi Hospital	Completed	No outcome recorded
Phase 4	NCT01463163 Comparator	Oct 2011 → Apr 2012	qualitative platelet defect	University of Patras	Completed	Missed primary
Phase 4	NCT01493999 Comparator	Sep 2011 → Jan 2013	acute coronary syndrome	University of Pecs	Completed	No outcome recorded
Phase 4	NCT01456364 Comparator	Sep 2011 → Apr 2014	coronary artery disorder	German Heart Center Munich	Unknown	No outcome recorded
Phase 4	NCT01365221 Comparator	Oct 2010 → Jan 2014	acute coronary syndrome	Medstar Health Research Institute	Completed	No outcome recorded
Phase 4	NCT01135667 Comparator	Sep 2010 → Jul 2012	acute coronary syndrome, coronary artery disorder	Lene Holmvang	Completed	No outcome recorded
Phase 4	NCT01201772 Comparator	Aug 2010 → May 2011	coronary artery disorder	University of Florida	Completed	No outcome recorded
Phase 4	NCT01158846 Comparator	Aug 2010 → Jun 2011	ST-elevation myocardial infarction, strictly posterior acute myocardial infarction	I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio	Unknown	No outcome recorded
Phase 4	NCT00977938 Comparator	Oct 2009 → Jun 2014	coronary artery disorder	Baim Institute for Clinical Research	Completed	No outcome recorded
Phase 4	NCT00954707 Comparator	Aug 2009 → Jan 2012	coronary artery disorder	Cordis US Corp.	Unknown	No outcome recorded
Phase 4	NCT01106534 Comparator	Aug 2009 → Feb 2015	arterial occlusion, coronary restenosis, myocardial ischemia	Abbott Medical Devices	Completed	No outcome recorded
—	NCT04708587 Comparator	Mar 2021 → Mar 2027 expected	chronic kidney disease	Yonsei University	Recruiting	No outcome recorded
—	NCT04100135 Background	Feb 2021 → Aug 2024	migraine disorder, patent foramen ovale	W.L.Gore & Associates	Terminated	No outcome recorded Stop: Enrollment
—	NCT03435133 Comparator	Nov 2015 → Oct 2018	ST-elevation myocardial infarction	AORTICA Group	Completed	No outcome recorded
—	NCT02303717 Background	Dec 2014 → Dec 2017	coronary artery disorder	NHS National Waiting Times Centre Board	Unknown	No outcome recorded
—	NCT02016170 Comparator	Mar 2014 → Oct 2015	acute coronary syndrome, coronary artery disorder	University of Florida	Completed	Met primary
—	NCT01852214 Comparator	Feb 2013 → Jul 2015	coronary artery disorder, type 2 diabetes mellitus	University of Florida	Completed	No outcome recorded
—	NCT01852175 Comparator	Jan 2012 → Jun 2014	coronary artery disorder	University of Florida	Completed	No outcome recorded
—	NCT01175200 Comparator	Sep 2010 → Jul 2012	platelet aggregation, spontaneous	Ascopharm Groupe Novasco	Completed	No outcome recorded
—	NCT01103843 Comparator	Apr 2010 → Apr 2011	coronary artery disorder	St. Francis Hospital, New York	Unknown	No outcome recorded

News releases announcing trial results or a regulatory action · 55

Date	Issuer	Release
2020-12-15	Daiichi Sankyo	Regulatory Daiichi Sankyo Submits Supplemental Application in Japan for Approval of Partial Changes Related to Additional Indication for the Antiplatelet Agent, Prasugrel Hydrochloride daiichisankyo.com ↗ Daiichi Sankyo Submits Supplemental Application in Japan for Approval of Partial Changes Related to Additional Indication for the Antiplatelet Agent, Prasugrel Hydrochloride
2020-07-21	Daiichi Sankyo	Results Daiichi Sankyo Announces Phase 3 Study Results for Prasugrel Antiplatelet Agent in Thrombotic Stroke Patients daiichisankyo.com ↗ The incidence of cerebral cardiovascular events (such as ischemic stroke, myocardial infarction, and other vascular deaths) was lower in the prasugrel group than in the clopidogrel group, thus achieving the primary endpoint in the study.
2016-10-21	Daiichi Sankyo	Results Daiichi Sankyo Announces Phase 3 Clinical Trial (PRASTRO-I Study, PRASTRO-II Study) Results for Prasugrel Antiplatelet Agent for Patients with Ischemic Cerebrovascular Disease daiichisankyo.com ↗ Tokyo, Japan (October 21, 2016) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), today announced the results of Phase 3 clinical trials in Japan of the antiplatelet agent prasugrel hydrochloride (hereafter, prasugrel) for ischemic cerebrovascular disease patients.
2015-06-01	Daiichi Sankyo	Regulatory Daiichi Sankyo Announces Lifting of Prescription Period Limitation for Antiplatelet Agent Efient® 3.75mg/5mg Tablets in Japan daiichisankyo.com ↗ Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the antiplatelet agent Efient® 3.75mg/5mg Tablets (JAN: Prasugrel Hydrochloride), which was launched in Japan in May 2014, has had its prescription period limitation of 14 days lifted based on a notification received from the Japanese Ministry of Health, Labour and Welfare.
2014-03-24	Daiichi Sankyo	Results Subgroup Analysis of PRASFIT-ACS Study Evaluated Impact of Platelet Reactivity on Prevention of Ischemic Events in Perioperative Period of PCI daiichisankyo.com ↗ the incidence of MACE (major adverse cardiovascular events) within 3 days after percutaneous coronary intervention (PCI) in the prasugrel group was 5.6% versus 8.3% for the clopidogrel group
2014-03-24	Daiichi Sankyo	Regulatory Daiichi Sankyo Receives Approval in Japan for Manufacturing and Marketing of the Antiplatelet Agent Efient® 3.75mg/5mg Tablets daiichisankyo.com ↗ Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has received approval from the Ministry of Health, Labour and Welfare in Japan for the antiplatelet agent Efient® 3.75mg/5mg Tablets (JAN: Prasugrel Hydrochloride) for the treatment of patients with ischemic heart disease undergoing PCI 1.
2013-07-12	Daiichi Sankyo	Results Daiichi Sankyo Announces Phase 3 Study Results (PRASFIT-Elective Study) for the Antiplatelet Agent Prasugrel in Japan daiichisankyo.com ↗ The incidence of the composite primary endpoint (cardiovascular death, non-fatal myocardial infarction, ischemic stroke) was 4.1 percent in the prasugrel group versus 6.7 percent in the clopidogrel sulfate (hereafter, clopidogrel) group.
2013-06-18	Daiichi Sankyo	Regulatory Daiichi Sankyo Submits a New Drug Application in Japan for the Antiplatelet Agent Prasugrel daiichisankyo.com ↗
2013-03-16	Daiichi Sankyo	Results Daiichi Sankyo Announces Positive Phase 3 Study Results (PRASFIT-ACS) for Prasugrel in Japanese Patients with Acute Coronary Syndrome Undergoing PCI daiichisankyo.com ↗ The incidence of the composite primary endpoint (cardiovascular (CV) death, non-fatal myocardial infarction, ischemic stroke) at 24 weeks in prasugrel patients was 9.4 percent, while 11.8 percent in clopidogrel patients (RR*=23 percent).
2013-03-14	Daiichi Sankyo	Results Daiichi Sankyo Announces Results of PRASFIT-Elective Study Regarding Use of Prasugrel in Elective Patients with Stable Angina and Chronic Myocardial Infarction Undergoing PCI daiichisankyo.com ↗ The follow-up period for this study has been completed and the anticipated data was obtained.
2012-10-23	Eli Lilly and Company	Results New Retrospective Studies of Hospital Readmission Rates for Subsequent Heart Attack and Initial Hospitalization Costs in ACS-PCI Patients Treated with Effient® (Prasugrel) or Plavix® (Clopidogrel) Presented at TCT lilly.com ↗ Effient-treated patients (n=9,404) had a significantly lower adjusted rate of rehospitalization for AMI than Plavix-treated patients (n=74,163) at 30 days (Odds Ratio [OR]: 0.89; p=0.047) and 90 days (OR: 0.90; p= 0.037) following ACS-PCI discharge.
2012-09-21	Daiichi Sankyo	Results Daiichi Sankyo Announces PRASFIT-ACS Results Regarding Prasugrel in Acute Coronary Syndrome Patients Undergoing PCI daiichisankyo.com ↗ The follow-up period for this study has been completed and the anticipated data was obtained.
2012-08-26	Daiichi Sankyo	Results Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient(R) (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening Procedure daiichisankyo.com ↗ This outcome was not statistically significant (P=0.21).
2012-08-26	Eli Lilly and Company	Results Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient® (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening Procedure lilly.com ↗ At 30 months, 13.9 percent of prasugrel patients vs. 16.0 percent of clopidogrel patients experienced the combined primary endpoint of heart attack, stroke or cardiovascular (CV) death in patients under 75 years of age, the primary analysis population (HR=0.91; 95% CI: 0.79-1.05).
2011-11-16	Eli Lilly and Company	Results New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI lilly.com ↗ TIMI major non-CABG bleeding events associated with prasugrel as compared to clopidogrel were consistent in the STEMI cohort compared to the overall trial.
2010-11-16	Eli Lilly and Company	Results Mortality Data Presented for Patients Treated with Effient® Who Underwent Isolated Coronary Artery Bypass Surgery lilly.com ↗ New results from an observational substudy from TRITON—TIMI 38 presented today at the American Heart Association (AHA) Scientific Sessions annual meeting showed that patients treated with Effient® (prasugrel) prior to coronary artery bypass graft surgery (CABG) had a reduced overall mortality rate compared to patients treated with Plavix® (clopidogrel) (2.3 percent versus 8.7 percent respectively, p=0.016).
2010-09-13	Eli Lilly and Company	Results Phase II Study Showed Switching ACS-PCI Patients to Effient(R)/aspirin from Plavix(R)/aspirin Regimen Reduced Maximum Platelet Aggregation After One Week lilly.com ↗
2010-03-15	Eli Lilly and Company	Results New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy lilly.com ↗ In contrast, Effient-treated patients with two C3435T variants (n=390) did not have a statistically significant increased risk of e
2010-01-05	Eli Lilly and Company	Results New Analysis Showed Effient(R) Cost-Effective Compared with Clopidogrel for Patients with Acute Coronary Syndromes Undergoing PCI lilly.com ↗ In the pre-specified analysis of 6,705 patients, treatment with Effient compared with clopidogrel reduced total hospitalization costs over approximately 15 months, not including the cost of study drugs, by $530 per patient.
2009-11-15	Eli Lilly and Company	Results Efient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease lilly.com ↗ In addition, one hour after the loading dose, patients who received prasugrel had 50 percent IPA compared with 13 percent in patients who received clopidogrel.
2009-11-15	Eli Lilly and Company	Results Effient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease lilly.com ↗ In addition, one hour after the loading dose, patients who received Effient had 50 percent IPA compared with 13 percent in patients who received clopidogrel.
2009-07-11	Daiichi Sankyo	Regulatory Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient™ daiichisankyo.com ↗ Daiichi Sankyo, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved Effient™(prasugrel) tablets for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes who are managed with an artery-opening procedure known as percutaneous coronary intervention (PCI).
2009-07-10	Eli Lilly and Company	Regulatory Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM) lilly.com ↗
2009-05-21	Eli Lilly and Company	Results Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial lilly.com ↗ In this post hoc analysis, the incidence of non-procedural heart attack in patients treated with prasugrel compared with patients treated with clopidogrel was 2.8 percent vs. 3.7 percent, respectively (p=0.0013).
2009-05-05	Eli Lilly and Company	Results New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel lilly.com ↗ Our findings showed that variation in the CYP2C19 gene did not appear to influence the rate of cardiac events in patients treated with prasugrel in this study.
2009-02-24	Daiichi Sankyo	Regulatory European Commission Approves EFIENT®(prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI daiichisankyo.com ↗ European Commission Approves EFIENT®(prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
2009-02-23	Eli Lilly and Company	Regulatory European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI lilly.com ↗ Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) announced today that the European Commission has granted marketing authorization for EFIENT(R) (pronounced Ef-ee-ent) (prasugrel) for the prevention of atherothrombotic events in patients with ACS undergoing percutaneous coronary intervention (PCI).
2009-02-04	Daiichi Sankyo	Regulatory Prasugrel Receives Unanimous Approval Recommendation from FDA Advisory Committee daiichisankyo.com ↗ The U.S. Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee voted 9 to 0 that prasugrel, an investigational antiplatelet agent should be approved for the treatment of patients with acute coronary syndromes (ACS) managed with an artery-opening procedure known as percutaneous coronary intervention (PCI), Daiichi Sankyo Company, Limited, (TSE: 4568), and Eli Lilly and Company (NYSE: LLY) announced today.
2009-02-03	Eli Lilly and Company	Regulatory Prasugrel Receives Unanimous Approval Recommendation from FDA Advisory Committee lilly.com ↗ The Advisory Committee voted unanimously that prasugrel should be approved for the treatment of patients with acute coronary syndromes undergoing PCI.
2008-12-19	Daiichi Sankyo	Regulatory Prasugrel Receives Positive Opinion from the European Committee for Medicinal Products for Human Use (CHMP) daiichisankyo.com ↗
2008-12-18	Eli Lilly and Company	Regulatory Prasugrel Receives Positive Opinion from the European Committee for Medicinal Products for Human Use (CHMP) lilly.com ↗ The CHMP positive opinion is now referred for final action to the European Commission, which grants approval in the European Union.
2008-09-27	Daiichi Sankyo	Regulatory FDA Continues to Review Prasugrel New Drug Application daiichisankyo.com ↗
2008-09-26	Eli Lilly and Company	Regulatory FDA Continues to Review Prasugrel New Drug Application lilly.com ↗ Daiichi Sankyo Company, Limited, (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) confirmed today that the U.S. Food and Drug Administration (FDA) did not complete its review for the prasugrel new drug application (NDA) by the Prescription Drug User Fee Act goal date of September 26, 2008.
2008-09-03	Eli Lilly and Company	Results Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel lilly.com ↗ Long-term treatment with prasugrel, continuing after 30 days for up to 15 months, significantly reduced the risk for patients who suffer any form of heart attack by 23 percent compared with clopidogrel (2.9 percent vs. 3.7 percent, p=0.01).
2008-09-03	Eli Lilly and Company	Results New Crossover Study Shows Prasugrel Significantly Reduced Platelet Aggregation in Patients with Acute Coronary Syndromes Compared with Clopidogrel at High Doses lilly.com ↗ Results of this study, known as the ACAPULCO(1) trial, showed that the 10 mg prasugrel maintenance dose significantly reduced the level of maximum platelet aggregation by 12.9 percent compared to the 150 mg clopidogrel maintenance dose (P<0.001).
2008-08-31	Eli Lilly and Company	Results Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel lilly.com ↗ In addition, according to this same analysis, the combined rate of cardiovascular death, non-fatal heart attack and non-fatal stroke was reduced by 30 percent in diabetes patients treated with prasugrel compared to those treated with clopidogrel (12.2 percent vs. 17.0 percent, P<0.001).
2008-08-25	Daiichi Sankyo	Results Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events daiichisankyo.com ↗ New analysis of landmark study showed patients taking prasugrel had lower risk of combined endpoint of recurrent heart attack, stroke or cardiovascular death after first event than those taking clopidogrel
2008-08-21	Eli Lilly and Company	Results Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events lilly.com ↗ The reduction in recurrent events among prasugrel patients persisted over the duration of the trial (15 months).
2008-06-24	Daiichi Sankyo	Regulatory FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel daiichisankyo.com ↗ This three month extension allows the FDA time to complete its review.
2008-06-23	Eli Lilly and Company	Regulatory FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel lilly.com ↗ This three month extension allows the FDA time to complete its review.
2008-03-31	Daiichi Sankyo	Results Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel daiichisankyo.com ↗ Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
2008-03-29	Eli Lilly and Company	Results Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel lilly.com ↗ Prasugrel reduced the relative risk of coronary stent thrombosis (a new clot at the implanted stent site) over clopidogrel by 52 percent (1.13 percent vs. 2.35 percent, p0.0001).
2008-02-22	Daiichi Sankyo	Regulatory FDA grants priority review for Daiichi Sankyo, Lilly drug, prasugrel Investigational antiplatelet agent submitted for treatment of patients with acute coronary syndrome being managed with percutaneous coronary intervention daiichisankyo.com ↗ FDA grants priority review for Daiichi Sankyo, Lilly drug, prasugrel
2008-02-21	Eli Lilly and Company	Regulatory FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel lilly.com ↗
2008-02-20	Daiichi Sankyo	Regulatory Daiichi Sankyo, Lilly Submit Marketing Authorization Application for Investigational Oral Antiplatelet Drug, Prasugrel, to European Medicines Agency daiichisankyo.com ↗ Daiichi Sankyo, Lilly Submit Marketing Authorization Application for Investigational Oral Antiplatelet Drug, Prasugrel, to European Medicines Agency
2008-01-07	Daiichi Sankyo	Regulatory Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration If Approved for Marketing in the United States, Trade Name Will be Effient™ daiichisankyo.com ↗
2008-01-04	Eli Lilly and Company	Regulatory Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration lilly.com ↗ Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) today announced that on Wednesday, Dec. 26, 2007, they submitted a New Drug Application (NDA) for prasugrel to the U.S. Food and Drug Administration (FDA).
2007-11-04	Daiichi Sankyo	Results In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack daiichisankyo.com ↗ A significant reduction in the risk for the composite endpoint favoring prasugrel (60 mg loading dose/10 mg maintenance dose) over clopidogrel (300 mg LD/75 mg MD) was observed as early as three days.
2007-11-04	Eli Lilly and Company	Results In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack lilly.com ↗ A significant reduction in the risk for the composite endpoint favoring prasugrel (60 mg loading dose/10 mg maintenance dose) over clopidogrel (300 mg LD/75 mg MD) was observed as early as three days.
2007-10-25	Daiichi Sankyo	Results Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies daiichisankyo.com ↗
2007-10-24	Eli Lilly and Company	Results Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies lilly.com ↗ The amendments are due to preliminary results from pharmacokinetic analyses, including patients and healthy subjects/volunteers, indicating that a dose adjustment may be appropriate for certain subpopulations.
2006-10-24	Daiichi Sankyo	Results New Study Shows Prasugrel Achieves Faster Onset and Higher Levels of Platelet Inhibition than Clopidogrel at Approved or Higher Doses daiichisankyo.com ↗ Thirty minutes after oral administration, the level of platelet inhibition with a prasugrel 60 mg dose was significantly higher than observed with either loading dose of clopidogrel.
2006-10-23	Eli Lilly and Company	Results New Study Shows Prasugrel Achieves Faster Onset and Higher Levels of Platelet Inhibition than Clopidogrel at Approved or Higher Doses lilly.com ↗ Thirty minutes after oral administration, the level of platelet inhibition with a prasugrel 60 mg dose was significantly higher than observed with either loading dose of clopidogrel.
2006-03-14	Eli Lilly and Company	Results Study Shows More Potent and More Reliable Platelet Inhibition with Prasugrel Compared to Clopidogrel Even in Patients With More Reactive Platelets lilly.com ↗ In early phase data announced today, the investigational antiplatelet agent, prasugrel, demonstrated greater and more reliable antiplatelet effect compared to clopidogrel (Plavix(R)) even in patients with increased platelet reactivity.
2005-03-09	Eli Lilly and Company	Results Results of Early Data Show More Consistent Platelet Inhibition with Prasugrel Compared to Clopidogrel Across Three Distinct Trials lilly.com ↗ In three early- phase trials,(1,2,3) an investigational platelet inhibitor, prasugrel (CS-747, LY640315), demonstrated significantly higher and more consistent inhibition of platelet aggregation (IPA) compared to both placebo and the current standard of care, clopidogrel (Plavix(R)).

All press releases naming this drug 72 releases

Date	Issuer	Release
2023-01-10	Lupin Limited	Lupin Receives Approval from U.S. FDA for Prasugrel Tablets, USP lupin.com ↗
2020-12-15	Daiichi Sankyo	Daiichi Sankyo Submits Supplemental Application in Japan for Approval of Partial Changes Related to Additional Indication for the Antiplatelet Agent, Prasugrel Hydrochloride daiichisankyo.com ↗
2020-07-21	Daiichi Sankyo	Daiichi Sankyo Announces Phase 3 Study Results for Prasugrel Antiplatelet Agent in Thrombotic Stroke Patients daiichisankyo.com ↗
2016-10-21	Daiichi Sankyo	Daiichi Sankyo Announces Phase 3 Clinical Trial (PRASTRO-I Study, PRASTRO-II Study) Results for Prasugrel Antiplatelet Agent for Patients with Ischemic Cerebrovascular Disease daiichisankyo.com ↗
2016-05-25	Daiichi Sankyo	Daiichi Sankyo Launches Antiplatelet Agent Efient® Tablets 20mg daiichisankyo.com ↗
2016-03-31	Eli Lilly and Company	New 2016 ACC/AHA Guideline Focused Update States that it is Reasonable to Choose Effient® (prasugrel) Over Clopidogrel for Certain ACS-PCI Patients with ST-Elevation Myocardial Infarction and NSTE-ACS lilly.com ↗
2015-06-01	Daiichi Sankyo	Daiichi Sankyo Announces Lifting of Prescription Period Limitation for Antiplatelet Agent Efient® 3.75mg/5mg Tablets in Japan daiichisankyo.com ↗
2014-05-27	Daiichi Sankyo	Daiichi Sankyo Launches the Antiplatelet Agent Efient® 3.75mg/5mg Tablets daiichisankyo.com ↗
2014-03-24	Daiichi Sankyo	Subgroup Analysis of PRASFIT-ACS Study Evaluated Impact of Platelet Reactivity on Prevention of Ischemic Events in Perioperative Period of PCI daiichisankyo.com ↗
2014-03-24	Daiichi Sankyo	Daiichi Sankyo Receives Approval in Japan for Manufacturing and Marketing of the Antiplatelet Agent Efient® 3.75mg/5mg Tablets daiichisankyo.com ↗
2013-07-12	Daiichi Sankyo	Daiichi Sankyo Announces Phase 3 Study Results (PRASFIT-Elective Study) for the Antiplatelet Agent Prasugrel in Japan daiichisankyo.com ↗
2013-06-18	Daiichi Sankyo	Daiichi Sankyo Submits a New Drug Application in Japan for the Antiplatelet Agent Prasugrel daiichisankyo.com ↗
2013-03-16	Daiichi Sankyo	Daiichi Sankyo Announces Positive Phase 3 Study Results (PRASFIT-ACS) for Prasugrel in Japanese Patients with Acute Coronary Syndrome Undergoing PCI daiichisankyo.com ↗
2013-03-14	Daiichi Sankyo	Daiichi Sankyo Announces Results of PRASFIT-Elective Study Regarding Use of Prasugrel in Elective Patients with Stable Angina and Chronic Myocardial Infarction Undergoing PCI daiichisankyo.com ↗
2012-10-23	Eli Lilly and Company	New Retrospective Studies of Hospital Readmission Rates for Subsequent Heart Attack and Initial Hospitalization Costs in ACS-PCI Patients Treated with Effient® (Prasugrel) or Plavix® (Clopidogrel) Presented at TCT lilly.com ↗
2012-09-21	Daiichi Sankyo	Daiichi Sankyo Announces PRASFIT-ACS Results Regarding Prasugrel in Acute Coronary Syndrome Patients Undergoing PCI daiichisankyo.com ↗
2012-08-26	Daiichi Sankyo	Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient(R) (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening Procedure daiichisankyo.com ↗
2012-08-26	Eli Lilly and Company	Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient® (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening Procedure lilly.com ↗
2011-11-16	Eli Lilly and Company	New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI lilly.com ↗
2011-03-29	Eli Lilly and Company	Effient® Added to Updated ACCF/AHA Clinical Guidelines for ACS-PCI Patients with Unstable Angina and Non-ST Segment Myocardial Infarction lilly.com ↗
2010-11-16	Eli Lilly and Company	Mortality Data Presented for Patients Treated with Effient® Who Underwent Isolated Coronary Artery Bypass Surgery lilly.com ↗
2010-09-13	Eli Lilly and Company	Phase II Study Showed Switching ACS-PCI Patients to Effient(R)/aspirin from Plavix(R)/aspirin Regimen Reduced Maximum Platelet Aggregation After One Week lilly.com ↗
2010-06-10	Daiichi Sankyo	Ranbaxy Launches Antiplatelet Agent Prasugrel in India daiichisankyo.com ↗
2010-03-15	Eli Lilly and Company	New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy lilly.com ↗
2010-01-05	Eli Lilly and Company	New Analysis Showed Effient(R) Cost-Effective Compared with Clopidogrel for Patients with Acute Coronary Syndromes Undergoing PCI lilly.com ↗
2009-11-18	Eli Lilly and Company	New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient(R) for Patients with Acute Coronary Syndromes Managed with PCI lilly.com ↗
2009-11-15	Eli Lilly and Company	Efient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease lilly.com ↗
2009-11-15	Eli Lilly and Company	Effient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease lilly.com ↗
2009-08-06	Daiichi Sankyo	Effient(TM) is Now Available in Pharmacies daiichisankyo.com ↗
2009-08-05	Eli Lilly and Company	Effient(TM) is Now Available in Pharmacies lilly.com ↗
2009-07-11	Daiichi Sankyo	Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient™ daiichisankyo.com ↗
2009-07-10	Eli Lilly and Company	Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM) lilly.com ↗
2009-05-21	Eli Lilly and Company	Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial lilly.com ↗
2009-05-05	Eli Lilly and Company	New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel lilly.com ↗
2009-04-08	Daiichi Sankyo	FIRST LAUNCH OF EFIENT® WORLDWIDE TAKES PLACE IN THE UK daiichisankyo.com ↗
2009-02-24	Daiichi Sankyo	European Commission Approves EFIENT®(prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI daiichisankyo.com ↗
2009-02-23	Eli Lilly and Company	European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI lilly.com ↗
2009-02-04	Daiichi Sankyo	Prasugrel Receives Unanimous Approval Recommendation from FDA Advisory Committee daiichisankyo.com ↗
2009-02-03	Eli Lilly and Company	Prasugrel Receives Unanimous Approval Recommendation from FDA Advisory Committee lilly.com ↗
2008-12-31	Eli Lilly and Company	FDA Cardio Renal Advisory Committee to Review Daiichi Sankyo, Lilly Drug Prasugrel lilly.com ↗
2008-12-19	Daiichi Sankyo	Prasugrel Receives Positive Opinion from the European Committee for Medicinal Products for Human Use (CHMP) daiichisankyo.com ↗
2008-12-18	Eli Lilly and Company	Prasugrel Receives Positive Opinion from the European Committee for Medicinal Products for Human Use (CHMP) lilly.com ↗
2008-10-17	Daiichi Sankyo	Daiichi Sankyo and Lilly Respond to Speculation On Status of Prasugrel New Drug Application daiichisankyo.com ↗
2008-10-16	Eli Lilly and Company	Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application lilly.com ↗
2008-09-27	Daiichi Sankyo	FDA Continues to Review Prasugrel New Drug Application daiichisankyo.com ↗
2008-09-26	Eli Lilly and Company	FDA Continues to Review Prasugrel New Drug Application lilly.com ↗
2008-09-03	Eli Lilly and Company	Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel lilly.com ↗
2008-09-03	Eli Lilly and Company	New Crossover Study Shows Prasugrel Significantly Reduced Platelet Aggregation in Patients with Acute Coronary Syndromes Compared with Clopidogrel at High Doses lilly.com ↗
2008-08-31	Eli Lilly and Company	Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel lilly.com ↗
2008-08-25	Daiichi Sankyo	Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events daiichisankyo.com ↗
2008-08-21	Eli Lilly and Company	Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events lilly.com ↗
2008-06-24	Daiichi Sankyo	FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel daiichisankyo.com ↗
2008-06-23	Eli Lilly and Company	FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel lilly.com ↗
2008-03-31	Daiichi Sankyo	Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel daiichisankyo.com ↗
2008-03-29	Eli Lilly and Company	Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel lilly.com ↗
2008-02-22	Daiichi Sankyo	FDA grants priority review for Daiichi Sankyo, Lilly drug, prasugrel Investigational antiplatelet agent submitted for treatment of patients with acute coronary syndrome being managed with percutaneous coronary intervention daiichisankyo.com ↗
2008-02-21	Eli Lilly and Company	FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel lilly.com ↗
2008-02-20	Daiichi Sankyo	Daiichi Sankyo, Lilly Submit Marketing Authorization Application for Investigational Oral Antiplatelet Drug, Prasugrel, to European Medicines Agency daiichisankyo.com ↗
2008-01-07	Daiichi Sankyo	Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration If Approved for Marketing in the United States, Trade Name Will be Effient™ daiichisankyo.com ↗
2008-01-04	Eli Lilly and Company	Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration lilly.com ↗
2007-11-04	Daiichi Sankyo	Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel daiichisankyo.com ↗
2007-11-04	Daiichi Sankyo	In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack daiichisankyo.com ↗
2007-11-04	Eli Lilly and Company	In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack lilly.com ↗
2007-11-04	Eli Lilly and Company	Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel lilly.com ↗
2007-10-25	Daiichi Sankyo	Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies daiichisankyo.com ↗
2007-10-24	Eli Lilly and Company	Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies lilly.com ↗
2007-01-18	Daiichi Sankyo	Enrollment Completed in Pivotal Phase III Study Comparing Prasugrel to Clopidogrel in Patients with Acute Coronary Syndrome daiichisankyo.com ↗
2007-01-16	Eli Lilly and Company	Enrollment Completed in Pivotal Phase III Study Comparing Prasugrel to Clopidogrel in Patients With Acute Coronary Syndrome lilly.com ↗
2006-10-24	Daiichi Sankyo	New Study Shows Prasugrel Achieves Faster Onset and Higher Levels of Platelet Inhibition than Clopidogrel at Approved or Higher Doses daiichisankyo.com ↗
2006-10-23	Eli Lilly and Company	New Study Shows Prasugrel Achieves Faster Onset and Higher Levels of Platelet Inhibition than Clopidogrel at Approved or Higher Doses lilly.com ↗
2006-03-14	Eli Lilly and Company	Study Shows More Potent and More Reliable Platelet Inhibition with Prasugrel Compared to Clopidogrel Even in Patients With More Reactive Platelets lilly.com ↗
2005-03-09	Eli Lilly and Company	Results of Early Data Show More Consistent Platelet Inhibition with Prasugrel Compared to Clopidogrel Across Three Distinct Trials lilly.com ↗

Evidence & citations 18 cited values

Every value below carries the sentence it was read from. 201 sources stand behind the page.

Field	Value	Cited text
Known as	prasugrel	“Randomization will be stratified by stent type (cobalt-chromium everolimus-eluting stents, platinum-chromium everolimus-eluting stents, and sirolimus-eluting stents with...” PMID 29447787 ↗ Dec 2017 197 “A total of 2268 STEMI patients indicated for primary PCI with current generation platinum‑chromium everolimus-eluting stents were randomized 1:1 to either prasugrel monotherapy...” PMID 41436299 ↗ Dec 2025 “Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice...” NCT00823212 ↗ “Every antiplatelet-naïve patient undergoing an elective procedure will be given 300 mg aspirin and loading dose of one of P2Y12 receptor inhibitors (e.g., 600 mg clopidogrel,...” NCT02601157 ↗ “Patients randomized to the antithrombotic monotherapy treatment receive any of the commercially available oral P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel) and...” NCT05955365 ↗ “Dual antiplatelet therapy with aspirin and either clopidogrel, prasugrel or ticagrelor will be recommended for 12 months duration in the Xience stent arm but only 4 months...” NCT02303717 ↗ “It consists in oral ingestion of 1.5g of paracetamol (Contents of 3 Doliprane® capsules 500 mg) and 60 mg prasugrel (6 tablets Efient ® 10 mg) or 180 mg ticagrelor ( 2 tablets...” NCT02251249 ↗ “Unlike prasugrel and ticagrelor, which are potent P2Y12 inhibitors, clopidogrel is activated in the liver via the cytochrome P450 2C19 (CYP2C19) metabolic pathway to exert its...” NCT06763744 ↗ “Day 1: Subjects received prasugrel (60 mg) either during the initial cangrelor infusion (at 1.0 hours or 1.5 hours after infusion start) or within 5 minutes of discontinuing...” NCT01852019 ↗ “Patients enrolled in dual antiplatelets at least 6 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for at least 6 months...” NCT04708587 ↗ “Treatment with clopidogrel 150mg once daily for a minimum of 10 days (max. 14 days), followed by a minimum of 10 days treatment with prasugrel 10mg once daily (max 14 days).” NCT05657041 ↗ Show 187 more sources
Known as	Effient	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201772 ↗
Known as	EFFIENT (prasugrel)	“EFFIENT (prasugrel)” NCT01589978 ↗
Known as	Efient	“It consists in oral ingestion of 1.5g of paracetamol (Contents of 3 Doliprane® capsules 500 mg) and 60 mg prasugrel (6 tablets Efient ® 10 mg) or 180 mg ticagrelor ( 2 tablets...” NCT02251249 ↗ 1 “Group 2: Prasugrel (Efient)” NCT01339026 ↗
Known as	Generic name: Prasugrel	“Generic name: Prasugrel” NCT01099566 ↗
Known as	LY-640315	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201772 ↗
Known as	NSC-759625	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201772 ↗
Known as	Prasu doc	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201772 ↗
Known as	Prasugrel (Effient)	“Prasugrel (Effient)” NCT01184300 ↗
Known as	Prasugrel = EFIENT	“Prasugrel = EFIENT” NCT01493999 ↗
Known as	PRASUGREL BESYLATE	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201772 ↗
Known as	Prasugrel hcl	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201772 ↗
Known as	Prasugrel Hydrochloride	“Prasugrel Hydrochloride 10 MG Oral Tablet” NCT04445623 ↗
Known as	Prasugrel viatris (previously prasugrel mylan)	ChEMBL registry synonym — accepted as the source's own label CHEMBL1201772 ↗
Action	Inhibit	“maintaining high levels of inhibition of platelet aggregation via P2Y(12) receptor inhibition” PMID 18498956 ↗ May 2008
Modality	Small molecule	“Prasugrel, a new thienopyridine” PMID 17982182 ↗ Nov 2007
Route	Oral	“Administered orally” NCT00059215 ↗
Target	P2RY12	“Recently, two new oral P2Y12 antagonists have been approved for clinical use: prasugrel, a third generation thienopyridine, and ticagrelor, a first in class...” NCT02016170 ↗